Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the SeQuent®Please in the Treatment of De-novo Stenoses Versus Taxus™Liberté™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Clinical evidence of stable or unstable angina or a positive functional study~* Single, stenotic de novo lesion in a native coronary artery, type A or selected B1 (see 4.3.1.1 Definition of lesion types)~* Diameter stenosis \> 70% (visual estimate)~* Vessel diameter 2.5 - 3.5 mm~* Female patients can enter this study if they are post-menopausal for at least two years or have undergone hysterectomy or sterilization~* Signed patient informed consent form~* Patient's and treating physician's agree that the patient will return for all required post procedure follow-up assessments as defined in the clinical protocol~Exclusion Criteria:~* Left ventricular ejection fraction of \< 30%~* Visible thrombus proximal to the lesion~* Expection that treatment with devices other than PTCA will be required for this lesion.~* Stenosis is within a bypass graft~* Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, paclitaxel, or a sensitivity to contrast media which cannot be adequately pre-medicated~* Other medical illness (i.e. cancer, liver disease or congestive heart failure) that may require cytostatic or radiation therapy, cause the subject to be non-compliant with the protocol, confound the data interpretation or is associated with limited life-expectancy (i.e., less than two years).~* Acute myocardial infarction within the past 72 hours of the intended treatment (de-fined as: Q wave infarction having total creatinine kinase (CK) \>3 times the upper normal limit, or CK remains elevated above hospital normal at time of treatment)~* Chronic renal insufficiency with serum creatinine \> 2.0 mg%~* Significant gastrointestinal (GI) bleed within the past six months.~* History of bleeding diathesis or coagulopathy or will refuse blood transfusions~* Extensive peripheral vascular disease that precludes safe 6 French sheath insertion and / or requires additional anti-platelet and / or anti-coagulation treatment.~* Participating in another device or drug study within the last 6 months which may inter-fere with the interpretation of results of this study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequent®Please (Type: ACTIVE_COMPARATOR): None
- Taxus™Liberté™ (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).